Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

GW274150

Catalog No. T11518LCas No. 210354-22-6

GW274150 is an orally active, selective and potent dual inhibitor of NADPH-dependent human nitric oxide synthase (iNOS) (Kd=40 nM) and rat inducible nitric oxide synthase (iNOS).GW274150 has a low activity against endothelial nitric oxide synthase (eNOS) and neuronal nitric oxide synthase (nNOS) in humans and rats. GW274150 showed protective effects in an inflammatory model of acute lung injury.

GW274150

GW274150

Purity: 96.43%
Catalog No. T11518LCas No. 210354-22-6
GW274150 is an orally active, selective and potent dual inhibitor of NADPH-dependent human nitric oxide synthase (iNOS) (Kd=40 nM) and rat inducible nitric oxide synthase (iNOS).GW274150 has a low activity against endothelial nitric oxide synthase (eNOS) and neuronal nitric oxide synthase (nNOS) in humans and rats. GW274150 showed protective effects in an inflammatory model of acute lung injury.
Pack SizePriceAvailabilityQuantity
1 mg$32In Stock
5 mg$73In Stock
10 mg$123In Stock
25 mg$255In Stock
50 mg$413In Stock
100 mg$662In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "GW274150"

Select Batch
Purity:96.43%
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
GW274150 is an orally active, selective and potent dual inhibitor of NADPH-dependent human nitric oxide synthase (iNOS) (Kd=40 nM) and rat inducible nitric oxide synthase (iNOS).GW274150 has a low activity against endothelial nitric oxide synthase (eNOS) and neuronal nitric oxide synthase (nNOS) in humans and rats. GW274150 showed protective effects in an inflammatory model of acute lung injury.
Targets&IC50
nNOS (rat):252 μM(ED50), iNOS (human):2.19 μM(kd), eNOS (human):544 μM(kd), iNOS (rat): 1.15 μM(ED50), iNOS (rat):1.15 μM(ED50), nNOS (human):177 μM(kd), iNOS:40 nM(kd), iNOS:(kd)40 nM
In vitro
GW274150 inhibits intracellular iNOS in J774 cells with an IC50 of 0.2 μM and demonstrates >260-fold and 219-fold selectivity for eNOS and nNOS, respectively, in rat tissue, as well as >100-fold and >80-fold selectivity for human eNOS and nNOS, respectively.[1]
In vivo
GW274150 is a long-acting (half-life in rats is 5 hours) iNOS inhibitor, which can inhibit the LPS-mediated increase in plasma NO2- and NO3- levels 14 h after a single intraperitoneal administration (ED50=3 mg/kg ).[2]
GW274150 (2.5, 5, and 10 mg/kg; i.p.; before carrageenan injection; SD rats) reduces the extent of carrageenan-induced lung injury in a dose-related manner. Pleural cavity edema formation and PMN infiltration were also significantly attenuated in a dose-related manner in rats.[2]
GW274150 (30 mg/kg; oral; twice daily; 7 days; SD rats) resulted in significant neuroprotection, however, it showed bell-shaped neuroprotection in 6-OHDA rats with Parkinson's disease (PD) Ineffective at high doses in the model.[3]
Chemical Properties
Molecular Weight219.3
FormulaC8H17N3O2S
Cas No.210354-22-6
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
DMSO: < 1 mg/mL (insoluble or slightly soluble)
H2O: 50 mg/mL (228 mM)
Solution Preparation Table
H2O
1mg5mg10mg50mg
1 mM4.5600 mL22.7998 mL45.5996 mL227.9982 mL
5 mM0.9120 mL4.5600 mL9.1199 mL45.5996 mL
10 mM0.4560 mL2.2800 mL4.5600 mL22.7998 mL
20 mM0.2280 mL1.1400 mL2.2800 mL11.3999 mL
50 mM0.0912 mL0.4560 mL0.9120 mL4.5600 mL
100 mM0.0456 mL0.2280 mL0.4560 mL2.2800 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy GW274150 | purchase GW274150 | GW274150 cost | order GW274150 | GW274150 chemical structure | GW274150 in vivo | GW274150 in vitro | GW274150 formula | GW274150 molecular weight